# Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

> **NCT00004985** · PHASE2 · COMPLETED · sponsor: **Agouron Pharmaceuticals** · enrollment: 75 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Capravirine
- **DRUG:** Nelfinavir mesylate

## Key facts

- **NCT ID:** NCT00004985
- **Lead sponsor:** Agouron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 75 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004985, "Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*